Factor Xa (fXa) plays a pivotal role in the activation of the coagulation system during
thrombosis, but, unlike GPIIb/IIIa receptor antagonists, the role of fXa inhibition in arterial passivation is not well defined. We compared the long-term antithrombotic efficacy of a direct fXa inhibitor,
FXV673, and
heparin after short-term infusion in conscious dogs. Dogs were instrumented surgically to induce
carotid artery thrombosis by electrolytic injury. On day 1, dogs received a 3-h infusion of placebo (n = 10),
FXV673 (100 microg/kg + 10 microg/kg/min, n = 7), or
heparin (60 U/kg + 0.7 U/kg/min, n 7). Injury (100 microA) was initiated concomitantly for 1 h. The procedure was repeated on day 2 with injury of 200 microA for 3 h. Carotid artery blood flow (CBF) and coagulation parameters were monitored continuously for 3 h on days 1 and 2 and for 30 min on days 3, 4, and 5. On day 1 at 3 h, CBF in the placebo-treated group was 26% of baseline with 70% incidence of occlusion. None of the vessels occluded in the
heparin and
FXV673 groups; however, the CBF was significantly higher in the
FXV673 group (92+/-8 ml/min versus 39+/-12 ml/min). Before injury on day 2, CBF recovered in all groups to 71-89% of baseline. After the
second injury, all vessels in the placebo-treated group progressed to complete occlusion by 3 h. CBF was significantly higher in
FXV673 group compared with
heparin throughout the 3-h period. On days 3, 4, and 5 the placebo-treated vessels remained occluded, but the CBF in the
heparin group was 33+/-20 ml/min, 55+/-11 ml/min and 68+/-12 ml/min, respectively, compared with 84+/-10 ml/min, 98+/-7 ml/min, and 99+/-10 ml/min in the
FXV673 group. The arterial
thrombus mass was significantly lower in
FXV673 group (13+/-4 mg) compared with placebo (103+/-10 mg) and
heparin (44+/-11 mg). In summary, these data demonstrate that short-term infusion of
FXV673 was associated with long-term efficacy that was superior to standard
heparin and underscore the role of direct fXa inhibition in arterial passivation.